Intelligent Remote Intervention for High-risk Breast Cancer Populations
NCT ID: NCT06193707
Last Updated: 2024-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
1250 participants
INTERVENTIONAL
2024-01-31
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Can the remote health intervention be more effective in slowing down the progression of breast nodules than the traditional in-person intervention?
* Can the remote health intervention be more effective in minimizing the deterioration of the disease and reducing the risk of death in patients than the traditional in-person intervention?
* Can the knowledge, belief and behavioral change of breast nodule population improve after receiving remote health intervention compared with traditional health management model?
Participants will be divided into 2 groups, the Experimental group and the Control group. Participants in the Experimental group will be offered with modern remote interventions for 2 years, as describe below:
* Teleconsultations: This involves using video calls, or phone calls once a month to connect patients for consultations, follow-ups, and discussions about conditions and symptom management.
* Remote Monitoring and Wearable Devices: Wearable devices and remote monitoring tools like Infrared Breast Temperature Detector and Dynamic blood pressure detector will be used once a week to track patients' vital signs and symptoms remotely.
* Mobile Applications: Specialized mobile apps will be used to provide a platform for patients to access educational materials, track their progress, manage management schedules, record symptoms, and connect with support groups or online communities.
* Educational Platforms and Remote Health Education: Online platforms and resources provide educational materials about breast cancer, treatment options, potential side effects, lifestyle adjustments, and overall wellness. These resources empower patients by providing comprehensive information.
Participants in the Control group will be offered with traditional strategies provided in the 'Breast Cancer Screening Guideline for Chinese Women': Ultrasound follow-up review is recommended no less than 3 to 6 months later. If there is no change at 2-year follow-up, it can be downgraded to BI-RADS 2; if there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort Study
NCT06510127
Remote Breast Cancer Screening Study
NCT04527510
Intensity Modulated Radiotherapy for Breast Cancer
NCT00594477
Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology
NCT05441098
Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images
NCT06510738
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goal of this clinical trial is to compare the effects of modern remote health intervention regime with traditional in-person intervention strategies in high-risk breast cancer groups that with BI-RADS 3 or higher nodules.
The main questions it aims to answer are:
* Can the remote health intervention be more effective in slowing down the progression of breast nodules than the traditional in-person intervention?
* Can the remote health intervention be more effective in minimizing the deterioration of the disease and reducing the risk of death in patients than the traditional in-person intervention?
* Can the knowledge, belief and behavioral change of breast nodule population improve after receiving remote health intervention compared with traditional health management model?
Research content:
The screened and qualified subjects were randomly divided into experimental group and control group, and different health management programs were adopted, the experimental group adopted the remote intervention health management mode, and the control group adopted the health management mode recommended by the conventional guidelines, to the end of the follow-up, and statistical analysis was performed to compare the effects of the two health management modes.
1\) To analyze the effectiveness of the remote intervention health management model in slowing down the malignant progression of breast nodules relative to the traditional model, and to analyze the differences in the rates of nodal lesion progression, nodal malignancy, and nodal improvement as well as the time spent on health management.
(2) To analyze the effectiveness of the tele-intervention health management model relative to the traditional model in reducing the risk of progression and death of patients with potential breast cancer after detection of the intelligent health management model, and to analyze the differences in the risk of death of the patients, the risk of progression of the lesions and the survival time.
(3) To analyze the degree of change in knowledge, beliefs, and behaviors of breast nodule populations after different health management intervention modes of tele-intervention health management mode relative to the traditional mode.
Study Population:
Female medical examiners who participated in physical examinations and had TI-RADS category 3 or higher breast nodules on breast color Doppler ultrasound at the health management centers of five large tertiary hospitals nationwide during the trial period. The study was a clinical trial study with qualitative variables as the main efficacy outcome indicators, and the subjects were randomized into a test group, a control group, and an equally parallel 1:1 design for both groups. Each group required 1,000 cases, and taking into account a 20% dropout rate, 1,250 cases were recruited in each group, totaling 2,500 cases in both groups.
Statistical analysis The study was a clinical trial study with qualitative variables as the primary outcome indicators of efficacy, with an equally parallel 1:1 design for both groups. The researchers considered that the smart health management program (trial group) had to be at least 5% better than the conventional health management program (control group) to be clinically meaningful. An equal (1:1) superiority design scheme was used, setting α = 0.025 (unilateral), β = 0.20 (unilateral), Δ = 5%, and estimating the sample size n. Based on the design of this clinical pilot study, combined with the primary efficacy outcome metrics, the estimation yielded a need for 500 cases in each group, and considering a 20% shedding rate, 625 cases were recruited in each group, for a total of 1,250 cases in both groups. Unless otherwise stated, all statistical tests were performed using a two-sided test with a test level of α = 0.05 (one-sided test α = 0.025). The study was a clinical trial study with qualitative variables as the main efficacy outcome indicators, and the effect of the new regimen had to be at least 5% better than that of the control drug to be clinically meaningful, so it was set at α = 0.025 (one-sided) and β = 0.20 (one-sided).
Hypotheses for the test of superiority H0: the efficiency of the test group is less than or equal to the control group, π\_T-π\_C≤0 H1: The efficiency of the test group is greater than that of the control group, π\_T-π\_C\>0 α = 0.025, the superiority cut-off value is 0. Calculate the difference between the effective rate of the experimental group and the control group, and calculate the 95% CI of the difference, if the lower limit of the 95% CI is greater than 0, the efficacy of the experimental group is considered to be better than that of the control group, and the expected goal of the study is achieved.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the Experimental Group
* Teleconsultations: This involves using video calls, or phone calls once a month to connect patients for consultations, follow-ups, and discussions about conditions and symptom management.
* Remote Monitoring and Wearable Devices: Wearable devices and remote monitoring tools like Infrared Breast Temperature Detector and Dynamic blood pressure detector will be used once a week to track patients' vital signs and symptoms remotely.
* Mobile Applications: Specialized mobile apps will be used to provide a platform for patients to access educational materials, track their progress, manage management schedules, record symptoms, and connect with support groups or online communities.
* Educational Platforms and Remote Health Education: Online platforms and resources provide educational materials about breast cancer, treatment options, potential side effects, lifestyle adjustments, and overall wellness. These resources empower patients by providing comprehensive information.
the Remote Intervention
Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
the Control Group
Ultrasound follow-up review is recommended no less than 3 to 6 months later. If there is no change at 2-year follow-up, it can be downgraded to BI-RADS 2; if there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
the Traditional Intervention
Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the Remote Intervention
Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
the Traditional Intervention
Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qianfoshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guang Zhang
Vice President
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guang Zhang, Dr
Role: PRINCIPAL_INVESTIGATOR
Qianfoshan Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578. Epub 2015 Dec 14.
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International Variation in Female Breast Cancer Incidence and Mortality Rates. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506. doi: 10.1158/1055-9965.EPI-15-0535. Epub 2015 Sep 10.
Taghipour S, Banjevic D, Miller AB, Montgomery N, Jardine AK, Harvey BJ. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study. Br J Cancer. 2013 Feb 19;108(3):542-8. doi: 10.1038/bjc.2012.596. Epub 2013 Jan 15.
Padilla A, Arponen O, Rinta-Kiikka I, Pertuz S. Image retrieval-based parenchymal analysis for breast cancer risk assessment. Med Phys. 2022 Feb;49(2):1055-1064. doi: 10.1002/mp.15378. Epub 2021 Dec 15.
Green VL. Breast Cancer Risk Assessment and Management of the High-Risk Patient. Obstet Gynecol Clin North Am. 2022 Mar;49(1):87-116. doi: 10.1016/j.ogc.2021.11.009.
Burka D, Gupta R, Moran AE, Cohn J, Choudhury SR, Cheadle T, Mullick R, Frieden TR. Keep it simple: designing a user-centred digital information system to support chronic disease management in low/middle-income countries. BMJ Health Care Inform. 2023 Jan;30(1):e100641. doi: 10.1136/bmjhci-2022-100641.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SDHMC-231201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.